Mangoceuticals, Inc. (MGRX)
Automate Your Wheel Strategy on MGRX
With Tiblio's Option Bot, you can configure your own wheel strategy including MGRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MGRX
- Rev/Share 0.1113
- Book/Share 4.409
- PB 0.4082
- Debt/Equity 0.0024
- CurrentRatio 0.1175
- ROIC -0.5152
- MktCap 17792059.0
- FreeCF/Share -1.3384
- PFCF -2.8942
- PE -0.7397
- Debt/Assets 0.0022
- DivYield 0
- ROE -0.7279
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch Market
Published: April 28, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York, Dallas, Texas, and Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - ArcStone Securities and Investments Corp. ("ArcStone"), a leading cross-border financial services firm, today announced the publication of an industry report on the rapidly emerging oral stimulant pouch market — a multi-billion dollar, high-growth vertical within the health and wellness consumer sector. In the report, ArcStone highlights Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals") following two transformative transactions: Acquisition of the North American rights to Diabetinol, expanding its health and wellness product pipeline; and Acquisition of selective executives, IP, and assets of Smokeless Technology Corp., establishing a leadership …
Read More
CORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector
Published: April 26, 2025 by: Newsfile Corp
Sentiment: Neutral
Transaction Marks ArcStone's Continued Cross-Border M&A Franchise Involving a NASDAQ-Listed Company, Underscoring the Strength of Its Global Platform and Financial Acumen In the news release, "ArcStone Securities and Investments Corp. serves as exclusive financial advisor to Mangoceuticals Inc." issued on 25-Apr-2025 by ArcStone over Newsfile, the company has advised that the main heading should not have included "acquisition of Smokeless Technology Corp." The complete, corrected release follows: Transaction Adds Executive Bench Strength, IP and Launches New Business Vertical for Mangoceuticals in Lucrative Oral Stimulant Pouch Segment on the Heels of the Significant Success of Turning Point Brands and Philip Morris …
Read More
Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ: MGRX) (“Mangoceuticals” or “MGRX”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. (“Smokeless Tech”), a Canadian-based pouch innovation company specializing in stimulant and functional pouches.
Read More
CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape
Published: April 22, 2025 by: Accesswire
Sentiment: Neutral
DALLAS, TX / ACCESS Newswire / April 22, 2025 / Mangoceuticals Inc. (NASDAQ:MGRX) is on a mission to rewrite the playbook for men's performance, health, and vitality. Its pursuit comes at a time when opportunities have become enormous, with patent expirations on several of the world's most popular health and wellness drugs, opening vast pathways to exploit segmented market opportunities, each worth billions.
Read More
About Mangoceuticals, Inc. (MGRX)
- IPO Date 2023-03-21
- Website https://www.mangorx.com
- Industry Medical - Healthcare Information Services
- CEO Jacob D. Cohen
- Employees 3